DT120
CompoundDefinium Therapeutics' lead LSD candidate — lysergide delivered as an orally-disintegrating tablet rather than the traditional blotter or liquid form. Originally developed under the code name MM120 before the company's January 2026 rebrand from MindMed to Definium.
Example: DT120 has posted two independent positive Phase 3 trials for generalized anxiety disorder — Voyage and Panorama — making it the most advanced LSD program in clinical development, though it's still not FDA-approved for anything.
What is DT120?
Definium Therapeutics' lead LSD candidate — lysergide delivered as an orally-disintegrating tablet rather than the traditional blotter or liquid form. It was originally developed under the code name MM120 before the company's January 2026 rebrand from MindMed to Definium.
Has DT120 been approved by the FDA?
No. It's posted two independent positive Phase 3 trials for generalized anxiety disorder — Voyage and Panorama — making it the most advanced LSD program in clinical development, but it isn't FDA-approved for anything yet.
Does DT120 have Breakthrough Therapy Designation?
Yes, for generalized anxiety disorder. See what that designation actually means.